首页> 美国卫生研究院文献>The British Journal of Ophthalmology >A multicentre report from the Mexican Retinoblastoma Group
【2h】

A multicentre report from the Mexican Retinoblastoma Group

机译:墨西哥视网膜母细胞瘤集团的多中心报告

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Background: Retinoblastoma (RB) is a relatively uncommon tumour in childhood. The incidence of retinoblastoma in Mexico is probably higher than the incidence reported worldwide, however there is not enough information about the characteristics of this illness in Mexico. This report aims to present the results of a multicentre clinical survey of RB in Mexico.>Methods: A retrospective study was carried out on all RB cases treated in 16 institutions during the last six years. The variables analysed were age at diagnosis, sex, affected eyes, treatment modalities, and pathological staging. Overall survival was obtained.>Results: The authors analysed 500 cases; age range was 0–182 months. There were 364 unilateral cases (72.8%). Enucleation was performed in 84.9% of the patients. The St Jude’s staging was: 7.4% stage I, 52.8% stage II, 18.0% stage III, 11.4% stage IV, 7.2% not evaluated, and 3.2% missing data. Chemotherapy was used in 74.4% of the patients. Disease free survival was 89% at 73 months follow up.>Conclusions: The paper presents a great number of cases and pioneers multicentre studies in paediatric ophthalmology and oncology in this country. Given the great number of patients in advanced stages and the variability on treatment schemes, it is evident that it is mandatory to work in a cooperative group and develop a national early detection programme as well as a treatment protocol which include all specialists involved in the care of patients with RB.
机译:>背景:视网膜母细胞瘤(RB)是儿童时期相对罕见的肿瘤。墨西哥视网膜母细胞瘤的发病率可能高于全世界报道的发病率,但是在墨西哥,这种疾病的特征尚无足够的信息。本报告旨在介绍墨西哥RB的多中心临床调查结果。>方法:回顾性研究了过去六年中在16家机构中治疗的所有RB病例。分析的变量包括诊断时的年龄,性别,受影响的眼睛,治疗方式和病理分期。获得了整体生存。>结果:作者分析了500例病例。年龄范围是0–182个月。单方面病例364例(72.8%)。 84.9%的患者进行了去核。 St Jude的分期为:第一阶段7.4%,第二阶段52.8%,第三阶段18.0%,第四阶段11.4%,未评估7.2%和数据丢失3.2%。 74.4%的患者使用化学疗法。在73个月的随访中,无病生存率为89%。>结论:该论文介绍了该国儿童眼科和肿瘤科的大量病例并进行了多中心研究。鉴于大量患者处于晚期并且治疗方案存在差异,很明显,必须在合作小组中开展工作并制定国家早期发现计划以及包括所有参与治疗的专家在内的治疗方案RB患者。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号